Cargando…

Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140185/
https://www.ncbi.nlm.nih.gov/pubmed/37052960
http://dx.doi.org/10.1182/bloodadvances.2022008775
_version_ 1785033109942566912
collection PubMed
description
format Online
Article
Text
id pubmed-10140185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-101401852023-04-29 Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931. Blood Adv Erratum The American Society of Hematology 2023-04-14 /pmc/articles/PMC10140185/ /pubmed/37052960 http://dx.doi.org/10.1182/bloodadvances.2022008775 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Erratum
Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
title Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
title_full Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
title_fullStr Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
title_full_unstemmed Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
title_short Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
title_sort karihtala k, leivonen s-k, karjalainen-lindsberg m-l, et al. checkpoint protein expression in the tumor microenvironment defines the outcome of classical hodgkin lymphoma patients. blood adv. 2022;6(6):1919-1931.
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140185/
https://www.ncbi.nlm.nih.gov/pubmed/37052960
http://dx.doi.org/10.1182/bloodadvances.2022008775